Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638 Japan.
Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203628119. doi: 10.1073/pnas.2203628119. Epub 2022 Oct 6.
Heart failure (HF) is a leading cause of death and repeated hospitalizations and often involves cardiac mitochondrial dysfunction. However, the underlying mechanisms largely remain elusive. Here, using a mouse model in which myocardial infarction (MI) was induced by coronary artery ligation, we show the metabolic basis of mitochondrial dysfunction in chronic HF. Four weeks after ligation, MI mice showed a significant decrease in myocardial succinyl-CoA levels, and this decrease impaired the mitochondrial oxidative phosphorylation (OXPHOS) capacity. Heme synthesis and ketolysis, and protein levels of several enzymes consuming succinyl-CoA in these events, were increased in MI mice, while enzymes synthesizing succinyl-CoA from α-ketoglutarate and glutamate were also increased. Furthermore, the ADP-specific subunit of succinyl-CoA synthase was reduced, while its GDP-specific subunit was almost unchanged. Administration of 5-aminolevulinic acid, an intermediate in the pathway from succinyl-CoA to heme synthesis, appreciably restored succinyl-CoA levels and OXPHOS capacity and prevented HF progression in MI mice. Previous reports also suggested the presence of succinyl-CoA metabolism abnormalities in cardiac muscles of HF patients. Our results identified that changes in succinyl-CoA usage in different metabolisms of the mitochondrial energy production system is characteristic to chronic HF, and although similar alterations are known to occur in healthy conditions, such as during strenuous exercise, they may often occur irreversibly in chronic HF leading to a decrease in succinyl-CoA. Consequently, nutritional interventions compensating the succinyl-CoA consumption are expected to be promising strategies to treat HF.
心力衰竭(HF)是死亡和反复住院的主要原因,常涉及心脏线粒体功能障碍。然而,其潜在机制在很大程度上仍难以捉摸。在这里,我们使用冠状动脉结扎诱导心肌梗死(MI)的小鼠模型,展示了慢性 HF 中线粒体功能障碍的代谢基础。结扎后 4 周,MI 小鼠心肌琥珀酰辅酶 A 水平显著下降,这一下降损害了线粒体氧化磷酸化(OXPHOS)能力。MI 小鼠的血红素合成和酮解作用以及消耗琥珀酰辅酶 A 的几种酶的蛋白水平增加,而从α-酮戊二酸和谷氨酸合成琥珀酰辅酶 A 的酶也增加。此外,琥珀酰辅酶 A 合酶的 ADP 特异性亚基减少,而其 GDP 特异性亚基几乎不变。5-氨基乙酰丙酸(琥珀酰辅酶 A 到血红素合成途径中的中间产物)的给药显著恢复了琥珀酰辅酶 A 水平和 OXPHOS 能力,并防止了 MI 小鼠的 HF 进展。先前的报告还表明 HF 患者心肌中存在琥珀酰辅酶 A 代谢异常。我们的结果表明,线粒体能量产生系统不同代谢中琥珀酰辅酶 A 使用的变化是慢性 HF 的特征,尽管在健康条件下(如剧烈运动期间)已知存在类似的改变,但在慢性 HF 中它们可能经常不可逆地发生,导致琥珀酰辅酶 A 减少。因此,补偿琥珀酰辅酶 A 消耗的营养干预有望成为治疗 HF 的有前途的策略。